AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 779750 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin (Calciparine)
Number of subjects: 36
Study 779750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 30549146 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative Care Skills Workshops
Number of subjects: 63
Study 30549146 — intervention group
Group type: COMPARATOR
Intervention: Psycho-educational Workshops
Number of subjects: 63
Study 30549146 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 63
Study 28503541 — intervention group
Group type: EXPERIMENTAL
Intervention: Core stabilization exercise (3 sessions per week for 12 weeks)
Number of subjects: 29
Study 28503541 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 29
Study 25894430 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 5 μg
Number of subjects: 285
Study 25894430 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 2.5 μg
Number of subjects: 285
Study 25894430 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study 22739993 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guided steroid injection
Number of subjects: 65
Study 22739993 — intervention group
Group type: EXPERIMENTAL
Intervention: Palpation guided steroid injection
Number of subjects: 65
Study 22739993 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 65
Study 22739993 — intervention group
Group type: EXPERIMENTAL
Intervention: Both active treatment groups (ultrasound guided and unguided)
Number of subjects: 65
Study 21708186 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy lifestyle pattern (HLP) score of 4
Number of subjects: 7000
Study 17457551 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery (MIS)
Number of subjects: 0
Study 17457551 — intervention group
Group type: COMPARATOR
Intervention: Standard access surgery
Number of subjects: 0
Study 16332655 — intervention group
Group type: EXPERIMENTAL
Intervention: High dietary calcium intake (1000-1400 mg/d)
Number of subjects: 19
Study 16332655 — intervention group
Group type: COMPARATOR
Intervention: Low dietary calcium intake (<800 mg/d, control)
Number of subjects: 19
Study 12547447 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9873847 — intervention group
Group type: EXPERIMENTAL
Intervention: plasma‐derived concentrates
Number of subjects: 65
Study 9873847 — intervention group
Group type: COMPARATOR
Intervention: fresh frozen plasma (FFP)
Number of subjects: 65
Study 9873847 — intervention group
Group type: EXPERIMENTAL
Intervention: low-dose concentrate at 25 IU kg‐1 twice weekly
Number of subjects: 65
Study 7625802 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 190
Study 7625802 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime
Number of subjects: 190
Study 2664088 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylphenidate (MTP)
Number of subjects: 50
Study 2664088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 850062 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation (experimental group)
Number of subjects: 572
Study 850062 — intervention group
Group type: COMPARATOR
Intervention: Continued inpatient care (control group)
Number of subjects: 572
Study 29975969 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided surgery
Number of subjects: 47
Study 29975969 — intervention group
Group type: COMPARATOR
Intervention: Wire localization surgery
Number of subjects: 47
Study 27628210 — intervention group
Group type: EXPERIMENTAL
Intervention: Injury prevention intervention (physician wearing a customized scrub top)
Number of subjects: 14
Study 27628210 — intervention group
Group type: COMPARATOR
Intervention: Control shift (no customized scrub top)
Number of subjects: 14
Study 26446582 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid hormone withdrawal (THW)
Number of subjects: 28
Study 26446582 — intervention group
Group type: COMPARATOR
Intervention: Recombinant human thyrotropin (rhTSH)
Number of subjects: 28
Study 23427483 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar replacement
Number of subjects: 63
Study 23427483 — intervention group
Group type: COMPARATOR
Intervention: Non patellar replacement
Number of subjects: 63
Study 22045142 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive electromagnetic device
Number of subjects: 49
Study 22045142 — intervention group
Group type: COMPARATOR
Intervention: Conventional blind technique
Number of subjects: 49
Study 19225395 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive support ventilation (ASV)
Number of subjects: 14
Study 19225395 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure support ventilation (PSV)
Number of subjects: 14
Study 19225395 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive pressure ventilation (APV)
Number of subjects: 14
Study 19225395 — intervention group
Group type: EXPERIMENTAL
Intervention: All modes (ASV, PSV, APV)
Number of subjects: 14
Study 17042908 — intervention group
Group type: EXPERIMENTAL
Intervention: Tulobuterol patch, 2 mg once daily
Number of subjects: 54
Study 17042908 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol, 50 mg twice daily
Number of subjects: 54
Study 15117110 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine
Number of subjects: 0
Study 15117110 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 0
Study 12230092 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG-gated myocardial perfusion SPECT after exercise
Number of subjects: 19
Study 12230092 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG-gated myocardial perfusion SPECT at rest and peak stress
Number of subjects: 19
Study 12230092 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG-gated myocardial perfusion SPECT
Number of subjects: 19
Study 12230092 — intervention group
Group type: COMPARATOR
Intervention: Comparison of LVESV changes between Groups N and I
Number of subjects: 19
Study 9477281 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2
Number of subjects: 105
Study 9477281 — intervention group
Group type: COMPARATOR
Intervention: Air
Number of subjects: 105
Study 9477281 — intervention group
Group type: EXPERIMENTAL
Intervention: 50/50 mixture
Number of subjects: 105
Study 7715220 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicaval technique (group A)
Number of subjects: 75
Study 2621401 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic traction
Number of subjects: 51
Study 2621401 — intervention group
Group type: COMPARATOR
Intervention: Immobilisation (Control)
Number of subjects: 51
Study 2621401 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic mobilisation
Number of subjects: 51
Study 2621401 — intervention group
Group type: COMPARATOR
Intervention: Fixed splintage (Control)
Number of subjects: 51
Study 839326 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula 1 (F1) = 1.5gm/dl protein, 60 parts bovine whey proteins: 40 parts bovine caseins
Number of subjects: 5
Study 839326 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula 2 (F2) = 3.0 gm/dl, 60:40
Number of subjects: 5
Study 839326 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula 3 (F3) = 1.5 gm/dl, 18:82
Number of subjects: 5
Study 839326 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula 4 (F4) = 3.0 gm/dl, 18:82
Number of subjects: 5
Study 839326 — intervention group
Group type: COMPARATOR
Intervention: Pooled human milk (BM)
Number of subjects: 5
Study 30949628 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine acid (CHX acid)
Number of subjects: 126
Study 30949628 — intervention group
Group type: EXPERIMENTAL
Intervention: Proanthocyanidin acid (PA acid)
Number of subjects: 126
Study 30949628 — intervention group
Group type: COMPARATOR
Intervention: Conventional phosphoric acid (CP acid)
Number of subjects: 126
Study 26984753 — intervention group
Group type: EXPERIMENTAL
Intervention: Project K youth development program
Number of subjects: 600
Study 26984753 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 600
Study 25771760 — intervention group
Group type: EXPERIMENTAL
Intervention: Mega heated and humidified breathing circuit (group M)
Number of subjects: 102
Study 25771760 — intervention group
Group type: EXPERIMENTAL
Intervention: Fisher & Paykel HHBC (group F)
Number of subjects: 102
Study 25771760 — intervention group
Group type: COMPARATOR
Intervention: Conventional breathing circuit (group C)
Number of subjects: 102
Study 23682096 — intervention group
Group type: EXPERIMENTAL
Intervention: LB03002 (SR-hGH) administered once weekly at a dose of 0.5 mg/kg
Number of subjects: 63
Study 23682096 — intervention group
Group type: COMPARATOR
Intervention: Daily rhGH administered for 6 consecutive days at a total of 0.21 mg/kg per week
Number of subjects: 63
Study 21235334 — intervention group
Group type: COMPARATOR
Intervention: Etoricoxib 120 mg
Number of subjects: 56
Study 21235334 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib 200 mg (and another 200 mg 12 hours after the first dose)
Number of subjects: 56
Study 21235334 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 56
Study 19710642 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 20 mg/day
Number of subjects: 15
Study 19710642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 17875873 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical methyl aminolevulinate PDT
Number of subjects: 97
Study 17875873 — intervention group
Group type: COMPARATOR
Intervention: Excision surgery
Number of subjects: 97
Study 15033894 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg (Group RO)
Number of subjects: 120
Study 15033894 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexketoprofen trometamol 25 mg (Group DE)
Number of subjects: 120
Study 15033894 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group PL)
Number of subjects: 120
Study 11392449 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral docetaxel in combination with cyclosporin A
Number of subjects: 0
Study 11392449 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral paclitaxel in combination with cyclosporin A
Number of subjects: 0
Study 11392449 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral route for both taxanes
Number of subjects: 0
Study 9597203 — intervention group
Group type: EXPERIMENTAL
Intervention: Adductor pollicis (AP)
Number of subjects: 40
Study 9597203 — intervention group
Group type: COMPARATOR
Intervention: Orbicularis oculi (OO)
Number of subjects: 40
Study 7946934 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS 1102, 30 micrograms kg‐1 and above
Number of subjects: 0
Study 7946934 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS 1102, 45 micrograms kg‐1 and above
Number of subjects: 0
Study 7946934 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS 1102, maximum tolerated dose 30 micrograms kg‐1
Number of subjects: 0
Study 7946934 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS 1102, administered as a 15 min intravenous infusion
Number of subjects: 0
Study 7946934 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS 1102
Number of subjects: 0
Study 17171905 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil, 20 microg/kg
Number of subjects: 48
Study 17171905 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl, 100 microg/kg
Number of subjects: 48
Study 17171905 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane, 1.6%
Number of subjects: 48
Study 17171905 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane, 0.9%
Number of subjects: 48
Study 30710315 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D laparoscopy
Number of subjects: 210
Study 30710315 — intervention group
Group type: COMPARATOR
Intervention: 2D laparoscopy
Number of subjects: 210
Study 30158356 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban Tosilate Hydrate
Number of subjects: 0
Study 26576860 — intervention group
Group type: EXPERIMENTAL
Intervention: LUCAS-CPR
Number of subjects: 12
Study 26576860 — intervention group
Group type: COMPARATOR
Intervention: Manual CPR
Number of subjects: 12
Study 25012446 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50mg/d
Number of subjects: 427
Study 25012446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 427
Study 22729716 — intervention group
Group type: EXPERIMENTAL
Intervention: EC + GA
Number of subjects: 60
Study 22729716 — intervention group
Group type: EXPERIMENTAL
Intervention: GA + EA
Number of subjects: 60
Study 22729716 — intervention group
Group type: EXPERIMENTAL
Intervention: EC + GA + EA
Number of subjects: 60
Study 22729716 — intervention group
Group type: COMPARATOR
Intervention: GA
Number of subjects: 60
Study 20418304 — intervention group
Group type: COMPARATOR
Intervention: Constant infusion rate group (normal saline 0.9% at an infusion rate 10 to 12 mL . kg(‐1) . h(‐1))
Number of subjects: 40
Study 20418304 — intervention group
Group type: EXPERIMENTAL
Intervention: Central venous pressure target (CVPT) group (normal saline 0.9% titrated to maintain a specific CVP of 5 mm Hg and 15 mm Hg during specific intervals)
Number of subjects: 40
Study 18069215 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral oestrogen therapy (2 mg daily)
Number of subjects: 45
Study 18069215 — intervention group
Group type: COMPARATOR
Intervention: Transdermal oestrogen therapy (0.05 mg daily)
Number of subjects: 45
Study 15723234 — intervention group
Group type: EXPERIMENTAL
Intervention: TachoSil (carrier‐bound fibrin sealant)
Number of subjects: 121
Study 15723234 — intervention group
Group type: COMPARATOR
Intervention: Argon beamer (argon beam coagulator)
Number of subjects: 121
Study 11857418 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for prostate cancer
Number of subjects: 163126
Study 11857418 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooling data with the PLCO trial
Number of subjects: 163126
Study 9713640 — intervention group
Group type: EXPERIMENTAL
Intervention: salmeterol 50 micrograms twice daily
Number of subjects: 225
Study 9713640 — intervention group
Group type: COMPARATOR
Intervention: comparator agents (placebo or salbutamol)
Number of subjects: 225
Study 7869204 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial liquid ventilation (PLV)
Number of subjects: 22
Study 7869204 — intervention group
Group type: COMPARATOR
Intervention: Conventional mechanical ventilation (CMV)
Number of subjects: 22
Study 7869204 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant (Exosurf) plus CMV
Number of subjects: 22
Study 7869204 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant plus PLV
Number of subjects: 22
Study 2237557 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 6
Study 2237557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 274262 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish (Duraphat) applied 5 or 6 times over 3 years
Number of subjects: 0
Study 274262 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31523888 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based Intelligent Tutoring System for the Text Structure Strategy (ITSS)
Number of subjects: 260
Study 30653578 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 12
Study 30653578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 27822702 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily WeChat services on cell phone for adherence to corticosteroid nasal spray treatment.
Number of subjects: 0
Study 27822702 — intervention group
Group type: COMPARATOR
Intervention: No WeChat services (control group).
Number of subjects: 0
Study 27822702 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide aqueous nasal spray 128 µg bid (given to all subjects).
Number of subjects: 0
Study 27067343 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin Enacarbil (GEn) 600 mg
Number of subjects: 671
Study 27067343 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin Enacarbil (GEn) 1200 mg
Number of subjects: 671
Study 27067343 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin Enacarbil (GEn) 600 mg and 1200 mg
Number of subjects: 671
Study 27067343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 671
Study 25471080 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous specific immunotherapy (SIT) with PURETHAL® Mites for 8 months
Number of subjects: 43
Study 25471080 — intervention group
Group type: COMPARATOR
Intervention: Medication to treat symptoms only (Control group)
Number of subjects: 43
Study 25471080 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (SIT and Control)
Number of subjects: 43
Study 25471080 — intervention group
Group type: EXPERIMENTAL
Intervention: SIT group
Number of subjects: 43
Study 22304836 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily grapefruit (1/2 fresh Rio-Red grapefruit with each meal, 3× daily for 6 weeks)
Number of subjects: 74
Study 22304836 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 74
Study 19513811 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral doses of tetrahydrobiopterin (BH(4))
Number of subjects: 17
Study 19513811 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical process control (SPC)
Number of subjects: 17
Study 19513811 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrahydrobiopterin (BH(4))
Number of subjects: 17
Study 17627490 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics
Number of subjects: 421
Study 17627490 — intervention group
Group type: COMPARATOR
Intervention: Caregiver support
Number of subjects: 421
Study 16336497 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg tegaserod
Number of subjects: 40
Study 16336497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 16824992 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic strain rate imaging before PCI
Number of subjects: 41
Study 16824992 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic strain rate imaging 3 days after PCI
Number of subjects: 41
Study 16824992 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic strain rate imaging 5 months after PCI
Number of subjects: 41
Study 16824992 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging after 5 months
Number of subjects: 41
Study 11039962 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid lowering drugs (duration: five to seven years)
Number of subjects: 0
Study 11039962 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid lowering drugs
Number of subjects: 0
Study 8667325 — intervention group
Group type: EXPERIMENTAL
Intervention: J95 health data collection system
Number of subjects: 0
Study 1825744 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% thymoxamine
Number of subjects: 78
Study 1825744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 6863582 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine 25 mg
Number of subjects: 7
Study 6863582 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine 75 mg
Number of subjects: 7
Study 6863582 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine 100 mg
Number of subjects: 7
Study 31776371 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 IU/d of vitamin D3
Number of subjects: 30
Study 31776371 — intervention group
Group type: EXPERIMENTAL
Intervention: 4,000 IU/d of vitamin D3
Number of subjects: 30
Study 31776371 — intervention group
Group type: EXPERIMENTAL
Intervention: 10,000 IU/d of vitamin D3
Number of subjects: 30
Study 31776371 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 30
Study 30613058 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication Empowerment Program based on Situated Learning Theory (8 sessions, twice a week, 2 hours each)
Number of subjects: 61
Study 26467666 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16/18 vaccine (Cervarix)
Number of subjects: 4186
Study 25178568 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (<40 g/d)
Number of subjects: 148
Study 25178568 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (<30% of daily energy intake from total fat)
Number of subjects: 148
Study 23043943 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide (administered prenatally between Days 80 and 88 of gestation and neonatally between Days 2 and 10 postnatally)
Number of subjects: 0
Study 23043943 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide (administered prenatally and neonatally)
Number of subjects: 0
Study 23043943 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide (neonatal exposure)
Number of subjects: 0
Study 23043943 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide (prenatal and neonatal exposure)
Number of subjects: 0
Study 23043943 — intervention group
Group type: COMPARATOR
Intervention: Control (nontreated pigs)
Number of subjects: 0
Study 20389163 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 40
Study 20389163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 17894911 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 40
Study 17894911 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 40
Study 15944796 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil/mitomycin adjuvant chemotherapy
Number of subjects: 160
Study 15944796 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 160
Study 12858127 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0
Study 12858127 — intervention group
Group type: EXPERIMENTAL
Intervention: High-density lipoprotein cholesterol
Number of subjects: 0
Study 10232563 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoral (NEO)
Number of subjects: 188
Study 10232563 — intervention group
Group type: COMPARATOR
Intervention: Sandimmune (SIM)
Number of subjects: 188
Study 8724018 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 15
Study 8724018 — intervention group
Group type: COMPARATOR
Intervention: Seated position
Number of subjects: 15
Study 8724018 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 15